Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
β-Catenin Inhibitor
β-Catenin-IN-2 is a potent inhibitor of β-catenin, a key regulator in the Wnt signaling pathway. This compound demonstrates significant biological activity in various cancer models, particularly in the study of colorectal cancer. Research applications include investigating the role of β-catenin in tumorigenesis and exploring potential therapeutic interventions targeting this pathway. -
β-catenin Inhibitor
β-catenin-IN-3 is a selective inhibitor of β-catenin, targeting a cryptic allosteric modulation site with a binding affinity of K D 54.96 nM. This compound effectively reduces the viability of β-catenin-driven cancer cells by promoting degradation of β-catenin through the proteasome pathway. β-catenin-IN-3 is valuable for research applications focused on cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
β catenin/BCL9 PPI Inhibitor
ZW4864 free base is a selective inhibitor of the β-catenin/BCL9 protein-protein interaction. It exhibits significant inhibitory activity with a Ki value of 0.76 μM and an IC50 value of 0.87 μM, making it a valuable tool for researching β-catenin signaling pathways. This compound is particularly relevant for studies related to cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin/Tcf PPI Inhibitor
UU-T02 is a selective small-molecule inhibitor targeting the β-catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI), exhibiting a Ki value of 1.36 μM. This compound effectively inhibits canonical Wnt signaling pathways, demonstrating significant potential in suppressing the growth of colorectal cancer cells. Its application in research is valuable for understanding Wnt-related mechanisms in cancer biology and developing therapeutic strategies. -
β-catenin/BCL9 Inhibitor
Antitumor agent-172 is a selective β-catenin/BCL9 inhibitor, demonstrating an IC50 of 3.92 μM and a high binding affinity with a Kd of 82 nM. This compound activates T cells and enhances antigen presentation, thereby exhibiting significant antitumor efficacy. It also displays favorable pharmacokinetic properties in mouse models, making it a valuable tool for cancer research and therapy. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
β-catenin/BCL9 Inhibitor
Antitumor agent-171 is a potent inhibitor of the β-catenin/BCL9 interaction, demonstrating an IC50 value of 1.61 μM. This compound exhibits a strong binding affinity to β-catenin, with a Kd of 0.63 μM, and effectively inhibits the expression of the axin2 gene with an IC50 of 0.84 μM. Additionally, Antitumor agent-171 reduces cell viability in HCT116 cells at an IC50 of 4.39 μM. Its ability to activate T cells and enhance antigen presentation underscores its potential in antitumor applications, with favorable pharmacokinetic properties observed in mouse models. -
β-catenin/Tcf PPI Inhibitor
UU-T01 is a selective inhibitor of the β-catenin/T-cell factor 4 (Tcf) protein-protein interaction, exhibiting a Ki value of 3.14 µM. This compound directly binds to β-catenin, with a dissociation constant (KD) of 0.531 µM. UU-T01 is valuable in research focused on Wnt signaling pathways and their implications in cellular processes such as proliferation and differentiation, offering potential insights into cancer biology and related disorders. -
β-catenin/Tcf PPI Inhibitor
β-catenin-IN-37 is a selective inhibitor of the β-catenin/T-cell factor (Tcf) protein-protein interaction. This compound effectively disrupts canonical Wnt signaling, exhibiting inhibitory activity against colorectal cancer cell lines SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively. β-catenin-IN-37 is valuable for studying Wnt signaling pathways and their implications in cancer research. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
β-catenin/TCF Signaling Inhibitor
CCT031374 hydrobromide is a potent inhibitor of the β-catenin/TCF signaling pathway. It effectively disrupts TCF-dependent transcription of target genes associated with the Wnt signaling cascade. CCT031374 demonstrates significant antitumor activity, making it valuable for research in cancer biology and therapeutic development targeting aberrant Wnt signaling. -
GSK3β Inhibitor
GSK3β-IN-2 is a potent GSK3β inhibitor with an IC50 of 0.35 nM. This compound activates the Wnt/β-catenin signaling pathway, leading to enhanced neurogenesis and neurite outgrowth. Additionally, GSK3β-IN-2 effectively inhibits Aβ-induced tau hyperphosphorylation at Ser396 and reduces neurofibrillary tangle formation. Its efficacy in ameliorating Alzheimer's disease has been demonstrated in zebrafish models, making it a valuable tool for neurological research. -
β-catenin Inhibitor
CGK012 is a selective β-catenin inhibitor that disrupts the Wnt/β-catenin signaling pathway. It effectively inhibits the release of HMGB1 and the transcriptional activity of β-catenin, demonstrating potential therapeutic benefits in sepsis induced by cecal ligation and puncture as well as in multiple myeloma. This compound is valuable for research applications focused on Wnt signaling regulation and its implications in various diseases. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-1 is a selective inhibitor targeting the PTK7/β-catenin signaling pathway, demonstrating an IC50 of 8.9 μM for PTK7/β-catenin and 56.5 μM for p53/MDM2. This compound shows promise in cancer research, particularly in studies examining the modulation of tumorigenic pathways influenced by β-catenin. Its inhibitory effects provide a valuable tool for investigating the role of PTK7 in cancer progression and therapeutic strategies. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-6 is a selective inhibitor of the PTK7/β-catenin interaction, effectively disrupting the Wnt signaling pathway. This compound demonstrates significant anticancer activity, particularly in colorectal cancer (CRC) models, making it a valuable tool for cancer research and therapeutic studies targeting Wnt-related pathways. -
β-catenin Inhibitor
β-catenin-IN-4 is a potent inhibitor of β-catenin, exhibiting an inhibition constant (Ki) of 0.64 μM. This compound effectively decreases the protein expression levels of key oncogenic factors such as cyclin D1 and c-Myc. β-catenin-IN-4 is valuable for research applications focused on cancer biology, particularly in studies investigating the Wnt signaling pathway and its role in tumor progression. -
Wnt/β-catenin Signaling Pathway Inhibitor
Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies. -
β-catenin Inhibitor
β-catenin-IN-6 is an inhibitor of β-catenin, effectively disrupting the canonical Wingless-related integration site signaling pathway. This compound demonstrates significant anti-proliferative effects on human colorectal cancer cells and has been shown to inhibit tumor growth in a β-catenin/RK3E mouse model, making it a valuable reagent for cancer research and therapeutic studies targeting β-catenin signaling pathways. -
β-catenin/BCL9 Complex Inhibitor
E722-2648 is a selective inhibitor of the β-catenin/BCL9 complex, targeting the interaction between these two proteins to inhibit β-catenin-mediated transcriptional activity. This compound demonstrates significant antitumor activity by downregulating the expression of WNT target genes, effectively suppressing tumor growth in colon cancer xenograft and colorectal cancer mouse models. E722-2648 serves as a valuable tool for investigating the molecular mechanisms of colon and colorectal cancers. -
Wnt Inhibitor
PTK7/β-catenin-IN-2 is a potent inhibitor of the PTK7/β-catenin interaction, effectively disrupting Wnt/β-catenin signaling with an IC50 of 5.6 μM. This inhibition impairs cell growth mediated by the Wnt pathway and demonstrates potential anticancer activity. Additionally, PTK7/β-catenin-IN-2 exhibits inhibitory effects on the p53-MDM2 interaction, with an IC50 of 157.1 μM, making it valuable for research focused on cancer therapies and signaling pathway modulation. -
GSK-3 Inhibitor
Laduviglusib dihydrochloride is a selective inhibitor of glycogen synthase kinase-3 (GSK-3), an enzyme involved in numerous cellular processes including glycogen synthesis, cell differentiation, and apoptosis. By inhibiting GSK-3, Laduviglusib dihydrochloride promotes cell survival and has been extensively studied in the context of neurodegenerative diseases, diabetes, and cancer research. This compound serves as a valuable tool for elucidating the role of GSK-3 in various signaling pathways and therapeutic applications. -
Wnt/β-catenin Signal Inhibitor
KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression. -
GSK3β Inhibitor
BRD1172 is a selective inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 24 nM. This compound effectively inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells and alleviates the negative regulation of GSK3β on β-catenin degradation and TCF/LEF promoter activity. BRD1172 is applicable in research related to Alzheimer’s disease, cardiac hypertrophy, and various cancers. -
β-catenin:TCF Interaction Inhibitor
β-Catenin inhibitory peptoid targets the β-catenin:TCF interaction, exhibiting an IC50 of 5.44 µM. This compound effectively inhibits Wnt signaling with an IC50 of 0.105 µM and androgen receptor signaling with an IC50 of 1.02 µM in prostate cancer cell lines. The peptoid significantly reduces cell proliferation, making it a valuable tool for research in cancer biology and therapeutic development. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-3 is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating low micromolar GI50 values across various cancer cell lines. This compound induces G2/M cell cycle arrest by activating the p53-p21 pathway and promotes apoptotic cell death through both intrinsic and extrinsic mechanisms in colon cancer cells. It serves as a valuable tool for investigating the role of Wnt/β-catenin signaling in cancer biology and therapeutic applications. -
Wnt/β-catenin Inhibitor
Getacatetide is a peptide-based inhibitor of the Wnt/β-catenin signaling pathway. This compound is designed to interfere with the activation of Wnt target genes, making it a valuable tool for investigating the role of Wnt/β-catenin signaling in solid tumors. Getacatetide's ability to disrupt this pathway facilitates research into cancer biology and the development of potential therapeutic strategies. -
Wnt Inhibitor
Halofenate acts as a Wnt inhibitor, impacting the Wnt signaling pathway crucial for cell proliferation and differentiation. It demonstrates significant biological activity by effectively reducing serum triglyceride levels by 50% in hypertriglyceridemic patients and decreasing serum uric acid by 30%, highlighting its potential uricosuric effects. Halofenate additionally increases plasma thyroxine (T4) levels, suggesting implications for thyroid function regulation, supported by in vitro studies showing its ability to displace T4 from thyroid-binding proteins. This compound can be valuable for research into metabolic disorders and thyroid function modulation. -
Axin Phosphorylation Inhibitor; β-catenin Phosphorylation Inhibitor
FRATtide is a peptide inhibitor targeting GSK-3, effectively disrupting the phosphorylation of Axin and β-catenin. By preventing the binding of GSK-3 to Axin, FRATtide modulates the Wnt signaling pathway, making it a valuable tool for research in cancer biology and developmental processes. This reagent is essential for studying mechanisms of β-catenin regulation and its implications in various diseases. -
Wnt Inhibitor
Jatrophone is a diterpenoid that functions as a Wnt inhibitor, exhibiting significant anticancer activity. Isolated from Jatropha isabelli, Jatrophone disrupts the Wnt/β-catenin signaling pathway, leading to a reduction in cell proliferation and inhibition of epithelial-mesenchymal transition (EMT) in triple-negative breast cancer cells. This compound is valuable for research focused on cancer biology and therapeutic strategies targeting Wnt pathway modulation. -
β-catenin Inhibitor
NLS-StAx-h is a selective β-catenin inhibitor designed to disrupt Wnt signaling pathways. This cell-permeable, stapled peptide exhibits an IC50 of 1.4 μM, effectively blocking β-catenin-transcription factor interactions. NLS-StAx-h demonstrates potent anti-proliferative effects on cancer cells, making it a valuable tool for research in cancer biology and therapeutic applications targeting aberrant Wnt signaling. -
GSK-3β Inhibitor
GSK-3β inhibitor 24 is a highly potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β), exhibiting an IC50 of 0.22 nM. This compound effectively enhances GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner, while reducing hyperphosphorylation of tau protein, specifically lowering p-tau-Ser396 levels. Additionally, GSK-3β inhibitor 24 promotes the upregulation of β-catenin and neurogenesis-related markers such as GAP43 and MAP-2, making it a valuable tool in Alzheimer's disease research and therapeutic studies. -
Wnt/β-Catenin Inhibitor
YW2036 is a potent inhibitor of the Wnt/β-Catenin signaling pathway, exhibiting an IC50 value of 637 nM. This compound has significant biological activity and is primarily utilized in research focused on colorectal cancer (CRC). Its role as a Wnt/β-Catenin inhibitor makes it a valuable tool for studies investigating the mechanisms underlying CRC progression and treatment approaches. -
β-catenin/Tcf4 Inhibitor
BC21 (NSC 109268) is a β-catenin/Tcf4 inhibitor with an IC50 of 5 μM. It disrupts the interaction between β-catenin and Tcf4-derived peptides, thereby inhibiting β-catenin/Tcf4-mediated transcriptional activity. This compound is particularly valuable in cancer research, where aberrant β-catenin signaling plays a critical role in tumor progression. -
Wnt/β-catenin Inhibitor
hsBCL9CT-24 is a potent inhibitor of the Wnt/β-catenin signaling pathway, targeting β-catenin to modulate oncogenic processes. This compound has demonstrated significant anti-tumor activity by reactivating the anti-cancer immune response impaired by aberrant Wnt signaling. hsBCL9CT-24 is applicable in cancer research, particularly in studies exploring Wnt pathway inhibition and immune evasion in tumor microenvironments. -
Wnt/β-catenin Inhibitor
1(R),2(S)-epoxy Cannabidiol is a potent inhibitor of the Wnt/β-catenin signaling pathway. This structural analogue of phytocannabinoids demonstrates significant biological activity, making it a valuable tool for research in neuroprotection. Its ability to modulate this critical pathway positions it as a promising candidate for studies focused on neuroprotective agents. -
β-catenin/Tcf4 Inhibitor
Murayaquinone is a potent inhibitor of the β-catenin/Tcf4 complex, exhibiting an IC50 of 2.4 μM. This compound, derived from Streptomyces sp. AN140557, demonstrates significant nematicidal activity. It serves as a valuable tool for research applications focused on Wnt signaling pathways and their roles in developmental biology and cancer research. -
Wnt/β-catenin Inhibitor
Sempervirine nitrate is a Wnt/β-catenin pathway inhibitor derived from the alkaloid Gelsemium elegans Benth. This compound exhibits significant anti-proliferative effects on hepatocellular carcinoma (HCC) cells and promotes apoptosis through modulation of the Wnt/β-catenin signaling cascade. Sempervirine nitrate is valuable for research into cancer biology and therapeutic approaches targeting HCC. -
Notch Inhibitor
Prednisone acetate is a glucocorticoid that functions as an orally active Notch inhibitor. It exhibits significant anti-inflammatory activity and has the potential to enhance immune responses. This compound is widely used in research to investigate its effects on Notch signaling and its implications in various inflammatory and immune-related conditions. -
γ-Secretase Inhibitor I
Z-LLNle-CHO is a γ-secretase inhibitor that effectively disrupts the Akt-mediated pro-survival signaling pathway, leading to caspase activation and ROS-dependent apoptosis. This compound is instrumental in cancer research, particularly in the studies of breast cancer and leukemia, where inhibiting γ-secretase activity may provide insights into therapeutic strategies. -
CK2 Inhibitor
CX-5011 is a selective inhibitor of casein kinase 2 (CK2), a serine/threonine kinase involved in cellular signaling pathways. This compound has been shown to activate Rac1, leading to effects on cell motility and morphology. Notably, CX-5011 induces apoptosis in various cancer cell lines, thereby promoting cancer cell death and making it a valuable tool for research in cancer biology and therapeutic interventions targeting CK2. -
GSK-3α/β Selective Inhibitor
GSK-3α/β-IN-1 is a selective inhibitor of glycogen synthase kinase-3 alpha and beta (GSK-3α/β), demonstrating IC50 values of 0.265 μM for GSK-3α and 0.255 μM for GSK-3β. Additionally, GSK-3α/β-IN-1 exhibits PKA inhibition with an IC50 of 0.188 μM. This compound effectively reduces cell viability in several glioblastoma (GBM) cell lines, with IC50 values ranging from 3 to 6 μM over 72 hours, while displaying minimal toxicity to human astrocytes. GSK-3α/β-IN-1 also shows promising central nervous system activity in human blood-brain barrier models of GBM, supporting its potential as a therapeutic agent in cancer research. -
γ-Secretase Inhibitor
EVP-0015962 is a potent γ-secretase inhibitor that effectively penetrates the blood-brain barrier, exhibiting an IC50 value of 3.9 μM. By modulating the γ-secretase-mediated cleavage of amyloid precursor protein, EVP-0015962 decreases the production of Aβ42 while increasing Aβ38 levels. This compound has demonstrated efficacy in reducing amyloid aggregates, mitigating amyloid plaque formation, and lowering inflammatory markers in mouse models, thereby enhancing cognitive function. EVP-0015962 serves as a valuable tool in Alzheimer's disease research. -
γ-secretase Inhibitor
JNJ-40418677 is a potent orally active inhibitor of γ-secretase, capable of crossing the blood-brain barrier. It effectively inhibits the production of Aβ42 and the activity of NS2B-NS3 protease, with IC50 values of 200 nM and 3.9 μM, respectively. This compound exhibits favorable biological tolerance and is suitable for research applications related to Alzheimer's disease. -
γ-secretase Inhibitor
Sulindac sulfide is a noncompetitive inhibitor of γ-secretase, exhibiting an IC50 of 20.2 μM for γ42-secretase activity. This compound plays a crucial role in research involving Alzheimer's disease and other neurodegenerative conditions by modulating the processing of amyloid precursor protein. Its ability to inhibit γ-secretase makes it a valuable tool for studies focused on reducing amyloid-beta peptide formation and investigating related signaling pathways. -
γ-secretase Inhibitor
ELND 006 is a selective γ-secretase inhibitor that effectively reduces amyloid beta (Aβ) generation while preserving Notch signaling pathways. Developed with a focus on metabolic stability, this compound has shown significant efficacy in lowering Aβ levels both in vitro and in vivo during preclinical studies. ELND 006, alongside its structural analog ELND 007, has advanced into human clinical trials, indicating its potential therapeutic applications in Alzheimer's disease research and treatment. -
gamma-Secretase Inhibitor
Gamma-secretase modulator 6 is a gamma-secretase inhibitor that effectively reduces the secretion of Aβ42 in HEK cells stably expressing amyloid precursor protein (APP), with a pIC50 value of 8.1. This compound plays a crucial role in the study of Alzheimer's disease by modulating gamma-secretase activity, thereby influencing amyloid plaque formation. It is a valuable tool for researchers exploring therapeutic strategies targeting amyloid pathology in neurodegenerative disorders. -
γ-secretase/Aβ42 Inhibitor
Amyloid-β-IN-2 is a selective γ-secretase inhibitor that effectively reduces the secretion of Aβ42 in H4 cells, exhibiting an EC50 value of 226 nM. This compound demonstrates potential for research applications in Alzheimer's disease and other conditions associated with Aβ deposition. Its ability to modulate γ-secretase activity makes it a valuable tool for studying the mechanisms underlying amyloid-related pathologies. -
γ-secretase/Aβ42 Inhibitor
Amyloid-β-IN-3 is a selective inhibitor of γ-secretase that effectively reduces the secretion of Aβ42 in H4 cells, exhibiting an EC50 value of 148 nM. By modulating γ-secretase catalytic activity, it decreases Aβ42 production and helps mitigate the neurotoxicity associated with amyloid deposition. This compound shows potential for research applications in Alzheimer's disease (AD) studies.
